Today: 19 April 2026
Sembcorp Industries stock price flat at S$6.10 as earnings near, Alinta deal stays in focus
10 February 2026
1 min read

Sembcorp Industries stock price flat at S$6.10 as earnings near, Alinta deal stays in focus

Singapore, February 10, 2026, 15:36 SGT — Regular session.

  • Sembcorp Industries was little changed at S$6.10 in afternoon trade.
  • The company is set to report FY2025 results on Feb. 25, with investors watching for guidance and cash flow signals.
  • Attention remains on the pending Alinta Energy acquisition and what it means for growth and approvals.

Sembcorp Industries Ltd shares were unchanged at S$6.10 at 3:22 p.m. Singapore time, after trading between S$6.09 and S$6.15. About 2.4 million shares had changed hands.

The next hard catalyst is close. Sembcorp said its FY2025 financial results will be released on Feb. 25 before trading hours, with a live webcast briefing scheduled for 11 a.m. (GMT+8).

Investors are also still weighing Sembcorp’s planned acquisition of Australia’s Alinta Energy. Sembcorp says the deal was approved by shareholders and is expected to complete in the first half of 2026, subject to regulatory approvals and other closing conditions. It also said Alinta operates 3.4 gigawatts of installed and contracted generation capacity and serves almost 1.1 million customers.

The broader Singapore market was steady. The Straits Times Index was down 0.03% in late afternoon, pointing to a muted tape for blue chips.

Across Asia, the tone was firmer, led by Japan. Global stocks rose in Asian trade and the Nikkei hit a fresh peak, while the dollar slipped, Reuters reported. “Overall, we actually are quite positive on the economic situation, although we see maybe some cracks,” said Kees Verbaas, Robeco’s global head of fundamental equity. Reuters

Sembcorp ended Monday at S$6.10, up 0.83%, and the stock’s 52-week range stands at S$5.21 to S$7.93, Investing.com data showed.

In the background, Sembcorp and seller Chow Tai Fook Enterprises said in a December press release that they had entered a share sale agreement for Sembcorp to acquire 100% of Alinta for an agreed enterprise value of A$6.5 billion — a deal measure that reflects the value of the business including debt. The companies said at the time the transaction was expected to complete in the first half of 2026, subject to shareholder and regulatory approvals.

For now, investors are likely to look for two things: what management says about cash generation and spending plans in renewables, and whether the Feb. 25 results give a cleaner read on the pace of growth heading into 2026.

But the downside case is straightforward. Any soft print, cautious outlook, or slippage in approvals around the Australia push could keep the shares stuck in the recent S$6 range, or worse, force investors to reprice the risk of a big cross-border deal.

The next test is Feb. 25, when Sembcorp is due to release its next earnings report.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
SGX stock price today: Singapore Exchange shares edge up after January trading surge
Previous Story

SGX stock price today: Singapore Exchange shares edge up after January trading surge

Compass Group share price stalls near 2026 low as AI worries keep CPG in focus
Next Story

Compass Group share price stalls near 2026 low as AI worries keep CPG in focus

Go toTop